Abstract
Objectives Numerous cases of pneumonia of caused by coronavirus disease 2019 (COVID-19) were reported in Wuhan, China. Chest computed tomography (CT) scan is highly important in the diagnosis and follow-up of lung disease treatment. The present meta-analysis was performed to evaluate chest CT findings in COVID-19 patients.
Materials and Methods All research steps were taken according to the MOOSE protocol and the final report was based on PRISMA guidelines. Each stage of the study was conducted by two independent authors. We searched the Web of Science, Ovid, Science Direct, Scopus, EMBASE, PubMed/Medline, Cochrane Library, EBSCO, CINAHL and Google scholar databases. The search was conducted on March 20, 2020. Grey literature was searched at medrxiv website. All analyses were performed using Comprehensive Meta-Analysis. The adapted Newcastle Ottawa Scale was used to evaluate the risk of bias. We registered this review at PROSPERO (registration number: CRD42019127858).
Results Finally, 40 eligible studies with 4,183 patients with COVID-19 were used for meta- analysis. The rate of positive chest CT scan in patients with COVID-19 was 94.5% (95%CI: 91.7-96.3). Bilateral lung involvement, pure ground-glass opacity (GGO), mixed (GGO pulse consolidation or reticular), consolidation, reticular, and presence of nodule findings in chest CT scan of COVID-19 pneumonia patients were respectively estimated to be 79.1% (95% CI: 70.8- 85.5), 64.9% (95%CI: 54.1-74.4), 49.2% (95%CI: 35.7-62.8), 30.3% (95%CI: 19.6-43.6), 17.0% (95%CI: 3.9-50.9) and 16.6% (95%CI: 13.6-20.2). The distribution of lung lesions in patients with COVID-19 pneumonia was peripheral (70.0% [95%CI: 57.8-79.9]), central (3.9% [95%CI: 1.4-10.6]), and peripheral and central (31.1% [95%CI: 19.5-45.8]). The most common pulmonary lobes involved were right lower lobe (86.5% [95%CI: 57.7-96.8]) and left lower lobe (81.0% [95%CI: 50.5-94.7]).
Conclusion Our study showed that chest CT scan has little weakness in diagnosis of COVID-19 combined to personal history, clinical symptoms, and initial laboratory findings, and may therefore serve as a standard method for diagnosis of COVID-19 based on its features and transformation rule, before initial RT-PCR screening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Ilam University of Medical sciences.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable.
Abbreviation
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- real-time PCR
- real-time polymerase chain reaction
- WHO
- World Health Organization
- COVID-19
- Coronavirus Disease 2019
- CT
- computed tomography
- MOOSE
- Meta-analyses Of Observational Studies in Epidemiology
- PRISMA
- the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PROSPERO
- The International Prospective Register of Systematic Reviews
- ICU
- intensive care unit
- GGO
- ground-glass opacity
- MERS-CoV
- Middle East Respiratory Syndrome
- SARS-CoV
- Severe Acute Respiratory Syndrome
